FIELD: medicine.
SUBSTANCE: there is described oral pharmaceutical composition containing 9,10-dehydroepothilone combined with a pharmaceutically acceptable carrier. According to the second version, the oral pharmaceutical composition contains trans-9,10-degihydroepothilone D and a pharmaceutically acceptable carrier containing hydroxypropyl-β-cyclodextrine, ethanol and propylene glycol. The concentrate for injection contains 9,10-degihydroepothilone D in the pharmaceutically acceptable carrier.
EFFECT: good bioavailability of epothilone D.
21 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS WHICH CONTAIN EPOTHILONE, AND METHOD OF THEIR OBTAINING | 2005 |
|
RU2416407C2 |
| LYOPHILIZED COMPOSITION | 1999 |
|
RU2268045C2 |
| EPOTHILONE-CONTAINING COMPOSITIONS | 1999 |
|
RU2214246C2 |
| METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
| AQUEOUS COMPOSITION CONTAINING DANTROLENE | 2016 |
|
RU2729043C2 |
| ENZYMATIC METHOD FOR PREPARING EPOTILONES, CRYSTALLINE FORM OF EPOTILONE B AND ITS USING | 1999 |
|
RU2268306C2 |
| DAPTOMYCIN PREPARATIONS | 2018 |
|
RU2770366C2 |
| NANOPARTICLES CARRYING CHEMOTHERAPEUTIC ANTI-CANCER THERAPEUTIC AGENT | 2012 |
|
RU2616494C2 |
| COMPOSITION FOR PARENTERAL ADMINISTRATION CONTAINING SIPONIMOD | 2018 |
|
RU2803937C2 |
| ESTRAMUSTINE COMPOSITIONS WITH IMPROVED PHARMACEUTICAL PROPERTIES | 1995 |
|
RU2179036C2 |
